Business Context and Reporting Period
This Form 8-K Current Report was filed by ARDELYX, INC. on December 17, 2025. The filing discloses significant executive departures and the appointment of interim leadership effective December 31, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation of Chief Legal and Administrative Officer: Elizabeth Grammer resigned effective December 31, 2025. She will serve as General Counsel until a successor is appointed, followed by a 24-month term as Senior Advisor.
- Resignation of Chief Medical Officer: Edward Conner, M.D., resigned effective December 31, 2025, for personal reasons unrelated to any disagreement with the Company.
- Interim Appointment: Dr. Laura Williams, Chief Patient Officer, will serve as interim Chief Medical Officer until a permanent replacement is hired.
Compensatory Arrangements and Outlook
Ms. Grammer entered into a Transition and Separation Agreement with the following key terms:
- Employment Period (First 12 months of Advisory Period): Continues to receive base salary and is eligible for a 45% target bonus for the year ending December 31, 2025. No ongoing bonus opportunity exists during the Senior Advisor role.
- Separation Payment: Upon providing a general release of claims at the end of the Employment Period, she will receive one month of her annual base salary.
- Consulting Phase (Second 12 months): Equity continues to vest. She is eligible for an advisory payment (amount to be determined) for the first nine months.
- Benefits: The Company will pay applicable COBRA premiums for healthcare coverage for herself and dependents during the full Advisory Period or until she becomes eligible for coverage elsewhere.
The filing does not provide specific financial guidance, risk factors, or contingencies beyond the personnel transitions.
Investor Verification Checklist
- Verify the exact base salary of Elizabeth Grammer to calculate the specific value of the one-month separation payment and the 45% bonus.
- Monitor the timeline for the appointment of a permanent successor to the Chief Medical Officer role.
- Review the full Transition and Separation Agreement when filed as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2025.
- Assess the impact of the interim Chief Medical Officer arrangement on the Company's clinical development programs.